search
Back to results

tDCS and Psychotherapy for the Treatment of Anxiety Disorders (tDCSplusUP)

Primary Purpose

Anxiety Disorders

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
active tDCS
sham tDCS
CBT-UP
Psychoeducation
Sponsored by
University of Coimbra
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anxiety Disorders focused on measuring anxiety disorders, tDCS, Unified Protocol, RCT

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of generalized anxiety disorder, specific phobia, panic disorder, agoraphobia, or social anxiety disorder.
  • Willing to participate and to give written informed consent

Exclusion Criteria:

  1. Contra-indications to tDCS use:

    • Presence of a cardiac or neurological condition
    • Metallic implants
    • If contact with scalp is not possible
    • Have had a head injury resulting in a loss of consciousness that has required further investigation
    • History of seizures
    • Epilepsy or a history of epilepsy
    • Past adverse effects with non-invasive stimulation treatments
  2. Current diagnosis of another psychiatric disorder (except for depression, as long as secondary diagnosis), psychoactive medication or psychological treatment
  3. Left-handedness
  4. Pregnancy
  5. Skin condition on the stimulation target area
  6. Recreational drug use

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Active Comparator

    Active Comparator

    Placebo Comparator

    Arm Label

    active tDCS + CBT-UP

    sham tDCS + CBT-UP

    active tDCS + Psychoeducation

    sham tDCS + Psychoeducation

    Arm Description

    Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.

    Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.

    Active tDCS combined with psychoeducation (control condition for CBT-UP).

    Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).

    Outcomes

    Primary Outcome Measures

    Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959)
    The mean change in the Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959) score, from baseline. HARS total score ranges from 0 to 56, where higher values indicate higher anxiety symptom's severity.

    Secondary Outcome Measures

    Response to treatment
    Defined as reduction of total Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959) score by ≥ 50%.
    Remission to treatment
    Defined as reduction of total Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959) to scores lower than 18 (indicating mild anxiety severity).
    Hamilton Depression Rating Scale (HRSD; Hamilton, 1960)
    The mean change in the Hamilton Depression Rating Scale (HRSD; Hamilton, 1960) score, from baseline. HDRS total score ranges from 0 to 75, where higher values indicate higher depressive symptoms' severity.

    Full Information

    First Posted
    June 26, 2020
    Last Updated
    May 19, 2022
    Sponsor
    University of Coimbra
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04453631
    Brief Title
    tDCS and Psychotherapy for the Treatment of Anxiety Disorders
    Acronym
    tDCSplusUP
    Official Title
    The Efficacy of Transcranial Direct Current Stimulation Combined With the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders: a Double Blind, Sham Controlled, Randomized Factorial Designed Study for Anxiety Disorders
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 3, 2023 (Anticipated)
    Primary Completion Date
    January 2024 (Anticipated)
    Study Completion Date
    July 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Coimbra

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The main goal of the study is to test the efficacy of tDCS in combination with the Unified Protocol for transdiagnostic treatment of emotional disorders, to reduce anxiety symptoms in a mixed anxiety disorders sample, as assessed by the Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959).
    Detailed Description
    Participants will be randomly allocated to one of four parallel experimental arms, within a 2X2 factorial design in which two interventions (tDCS and CBT-UP) will be delivered, and assessed according to two levels (e.g., intervention vs. no intervention). Each study participant will assigned to one factor level. Four intervention groups are defined active tDCS + CBT-UP sham tDCS + CBT-UP active tDCS + Psychoeducation sham tDCS + Psychoeducation The four arms allow to experimentally control the two active therapeutic interventions: active tDCS and CBT-UP. Sham tDCS is the control for active tDCS and psychoeducation is the control condition for CBT-UP. The intervention will last for 15 weeks, and all groups will comply with the same intervention structure according to the examination plan established in the protocol: week 1-2: 1 CBT-UP session/week week 3-4: 5 tDCS sessions and 1 CBT-UP session/week week 5-8: 2 tDCS sessions and 1 CBT-UP session/week week 9-14: 1 tDCS session and 1 CBT-UP session/week week 15: 1 CBT-UP session The treatment will consist of 26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle. tDCS will be combined with cognitive-behavioral therapy, in particular following the unified protocol for transdiagnostic treatment of emotional disorders (Barlow et al. 2018). Safety: No serious adverse effects are expected with conventional tDCS protocols in humans (≤40 min, ≤4 mA; conclusions from a meta-analysis observing >33200 sessions, >1000 subjects with repeated sessions; Bikson et al., 2016). Plans for treatment or care after the subject has ended his/her participation in the trial: Patients will be recommended and offered the best treatment as evidenced by the trial results. For patients that already completed that intervention further standard psychological/psychiatric treatment will be recommended according to patients' status.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Anxiety Disorders
    Keywords
    anxiety disorders, tDCS, Unified Protocol, RCT

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    active tDCS + CBT-UP
    Arm Type
    Experimental
    Arm Description
    Active tDCS combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
    Arm Title
    sham tDCS + CBT-UP
    Arm Type
    Active Comparator
    Arm Description
    Sham tDCS (control for active tDCS) combined with the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.
    Arm Title
    active tDCS + Psychoeducation
    Arm Type
    Active Comparator
    Arm Description
    Active tDCS combined with psychoeducation (control condition for CBT-UP).
    Arm Title
    sham tDCS + Psychoeducation
    Arm Type
    Placebo Comparator
    Arm Description
    Sham tDCS combined with psychoeducation (control conditions for active tDCS and CBT-UP).
    Intervention Type
    Device
    Intervention Name(s)
    active tDCS
    Other Intervention Name(s)
    Transcranial Direct Current Stimulation
    Intervention Description
    26 transcranial direct current stimulation sessions, each lasting 20 minutes, with a current intensity of 2 mA, the cathode placed over the right dorsolateral prefrontal cortex and the anode placed over the left deltoid muscle.
    Intervention Type
    Device
    Intervention Name(s)
    sham tDCS
    Intervention Description
    tDCS is controlled in this intervention: sham mode.
    Intervention Type
    Behavioral
    Intervention Name(s)
    CBT-UP
    Intervention Description
    15 psychotherapy sessions (1/week) following the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders developed by Barlow et al. 2018.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Psychoeducation
    Intervention Description
    To control for the cognitive-behavioral intervention we will use psychoeducation materials.
    Primary Outcome Measure Information:
    Title
    Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959)
    Description
    The mean change in the Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959) score, from baseline. HARS total score ranges from 0 to 56, where higher values indicate higher anxiety symptom's severity.
    Time Frame
    At week 8th, 15th (middle and end of treatment) and 6 months follow-up
    Secondary Outcome Measure Information:
    Title
    Response to treatment
    Description
    Defined as reduction of total Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959) score by ≥ 50%.
    Time Frame
    At week 8th, 15th (middle and end of treatment) and 6 months follow-up.
    Title
    Remission to treatment
    Description
    Defined as reduction of total Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959) to scores lower than 18 (indicating mild anxiety severity).
    Time Frame
    At week 8th, 15th (middle and end of treatment) and 6 months follow-up.
    Title
    Hamilton Depression Rating Scale (HRSD; Hamilton, 1960)
    Description
    The mean change in the Hamilton Depression Rating Scale (HRSD; Hamilton, 1960) score, from baseline. HDRS total score ranges from 0 to 75, where higher values indicate higher depressive symptoms' severity.
    Time Frame
    At week 8th, 15th (middle and end of treatment) and 6 months follow-up.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Diagnosis of generalized anxiety disorder, specific phobia, panic disorder, agoraphobia, or social anxiety disorder. Willing to participate and to give written informed consent Exclusion Criteria: Contra-indications to tDCS use: Presence of a cardiac or neurological condition Metallic implants If contact with scalp is not possible Have had a head injury resulting in a loss of consciousness that has required further investigation History of seizures Epilepsy or a history of epilepsy Past adverse effects with non-invasive stimulation treatments Current diagnosis of another psychiatric disorder (except for depression, as long as secondary diagnosis), psychoactive medication or psychological treatment Left-handedness Pregnancy Skin condition on the stimulation target area Recreational drug use

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    Citations:
    PubMed Identifier
    13638508
    Citation
    HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. doi: 10.1111/j.2044-8341.1959.tb00467.x. No abstract available.
    Results Reference
    background
    PubMed Identifier
    14399272
    Citation
    HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56. No abstract available.
    Results Reference
    background
    PubMed Identifier
    27372845
    Citation
    Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet L, Fregni F, Fritsch B, Gillick B, Hamilton RH, Hampstead BM, Jankord R, Kirton A, Knotkova H, Liebetanz D, Liu A, Loo C, Nitsche MA, Reis J, Richardson JD, Rotenberg A, Turkeltaub PE, Woods AJ. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-661. doi: 10.1016/j.brs.2016.06.004. Epub 2016 Jun 15.
    Results Reference
    background
    PubMed Identifier
    28768327
    Citation
    Barlow DH, Farchione TJ, Bullis JR, Gallagher MW, Murray-Latin H, Sauer-Zavala S, Bentley KH, Thompson-Hollands J, Conklin LR, Boswell JF, Ametaj A, Carl JR, Boettcher HT, Cassiello-Robbins C. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders Compared With Diagnosis-Specific Protocols for Anxiety Disorders: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Sep 1;74(9):875-884. doi: 10.1001/jamapsychiatry.2017.2164.
    Results Reference
    background

    Learn more about this trial

    tDCS and Psychotherapy for the Treatment of Anxiety Disorders

    We'll reach out to this number within 24 hrs